Author: Editor

Stephen J. Russell, MD, PhD of Mayo Clinic explains why recombinant measles and recombinant vesicular stomatitis virus are ideal adjunct to checkpoint immunotherapy. Both have shown impressive activity in pre-clinical models and clinical studies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute discusses how stress reducing beta blockers combined with immunotherapy may increase response rates in cancer patients. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute explains how patients on beta blockers may do better with immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute gives an overview of her presentation that was presented at ASCO-SITC Symposium. Her presentation focused on mild stress in mouse models, specifically thermal stress, which mirrors stress in humans. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Graham P. Pawelec, PhD of Universitätsklinikum Tübingen explains how new data suggests immunosenescence may not be a factor in immunotherapy treatment. Immunosenescence suggests that older people have an immune system that does not work quite as well as the immune system in younger people. He states that this is a relatively unexplored area in cancer research, but could explain why some patients’ response rates are lower than others. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of combination strategies in treatment for negative breast cancer. Specifically, in a study that combines pembrolizumab and radiation, it shows great promise for the future of combination therapy in breast cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the most interesting research she has seen at the ASCO-SITC Symposium. This presentation explained the effects of a microbiome as a predictor of response to checkpoint blockade strategies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center gives an overview of a poster discussion that was presented at the ASCO-SITC Symposium. This discussion described the results of a randomized study where docetaxel is used with or without plinabulin for patients with non-small cell lung cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses a Phase 1 Study that was being presented at ASCO-SITC. This study combines Carboplatin, Paclitaxel, and an HPV vaccine in the therapeutic setting. She states that even though it is a provocative and early study, the data shows great promise. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of checkpoint blockade in breast cancer. With the biomarker PDL-1, there has been a 19% response rate in women with triple negative breast cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses promising approaches for looking at tumor microenvironment. He mentions a study that showed patients who received standard of care therapy plus immunotherapy had a better response rate than those who only received standard of care. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses the new research regarding immunotherapies. He states that specifically in colorectal cancer, healthcare professionals are including combinations of vaccines and chemotherapy for treatment. Other treatments include vaccines and checkpoint inhibitors. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health gives an overview of the new and upcoming trends of 2017 for immunotherapy. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering talks about the different types of combinations in immunotherapy. She suggests that two combined treatments are better than one in overcoming resistance. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering advises healthcare professionals to use Nivolumab and Ipilimumab in treating patients with advanced melanoma, especially since there is a 20% response rate. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering discusses the importance of novel combinations for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco discusses the use of more combinations therapies, like Nivolumab and Ipilimumab. This combination therapy is FDA approved for Melanoma, but combination therapies like these may be used for treating new cancers such as Lung, Bladder, and Kidney. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco explains how there are several combination therapies to study, but not enough patient-participants for these clinical trials. He hopes for a more rational path regarding patients in order to see which combination therapies will work. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco discusses upcoming combination therapies for melanoma treatment that will be FDA approved and used in clinical practice at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego explains how immunotherapy is expanding for cancer treatment into new cancer diseases, especially ones that are more challenging to treat. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego states that in 2017, we will see more combination immuno-therapy for cancer treatment. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego explains how biomarkers and combination therapy may be the path ahead for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego gives an overview of presentations that were discussed at ASCO-SITC. He states that the conference focuses on the new and upcoming research and data in immuno-oncology, such as a new PDL-1, Avelumab. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the abstracts and new data that were presented at the second oral session for ASCO-SITC. The research focused on mutations in tumor and how those affects patients’ responses to treatment. This was recorded ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the promising and exciting new results from CAR T-Cell data for treatment of not only mesothelioma but other difficult-to-treat diseases. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Keith Argenbright, MD of UT Southwestern Medical Center discusses the geographical barriers for cancer survivorship. In these undeserved areas, which are mostly rural, these patients have circumstances that are hard for most to understand. He hopes that at ASCO, more people will become aware of these barriers. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center discusses his presentation “Driving Survivorship Home,” which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center explains how he finds patients for his Mobile Survivorship program. He states that he works with community oncologists, nurse practitioners, and public health clinics for outeach. He hopes to work with anyone who wants to work with them, and that his program will work around the patients’ needs and wants in order for them to have the best outcome. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center discusses the advantages of a mobile survivorship program. He states that there are 9 counties in Dallas, Texas where 55% of these areas are “medically underserved,” resulting in the creation of the Mobile Survivorship Program. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses the research he found most intriguing at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses how radiation has changed for invasive bladder cancer treatment. He explains the new and exciting research on biomarkers and its use for figuring out which patients will benefit from radiation therapy of bladder cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses which patients with low-risk prostate cancer should receive radiation. He argues that radiation may not be for every patient and doctors should discuss all the options that are available to their patients. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University explains the difference between the side effects of radiation and surgery/active surveillance and which treatment impacts a prostate cancer patient’s quality of life (QOL). This was recorded at the 2017 Genitourinary (GU) Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University diseases how the use of radiation has been adopted in the treatment for advanced prostate cancer. This was recorded at the 2017 Genitourinary (GU) Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University gives an overview of his presentation “Best of Journals: Prostate Cancer,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains his perspective on how to integrate drugs into treating patients with metastatic prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how treatment for prostate cancer has changed since the emerging data on resistance. Based on his knowledge of the disease, he believes that prostate cancer will inevitably evolve to resistance. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how and when immunotherapy will be used for metastatic prostate cancer treatments at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses how the clinical trials, CHAARTED and STAMPEDE, have impacted his treatment for patients with metastatic hormone sensitive prostate cancer. He states that his patients who received chemotherapy from the study are doing remarkably well and are one step closer to eliminating the entire disease. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses when and where does chemotherapy fit into treatment for prostate cancer. He argues that chemotherapy should be used earlier in the disease. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why he believes that all metastatic castration-resistant prostate cancer patients should receive chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida. Who are the right metastatic castration-resistant prostate cancer patients that should be treated with chemotherapy

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why BRCA 1 and BRCA 2 genetic testing should be added to the guidelines for treating prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains what the biggest challenges are in facing patients and providers in the diagnosis and treatment strategies for patients with metastatic renal cell carcinoma. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses how immunotherapies are being integrated renal cell carcinoma treatment. She states that immunotherapy currently is in second or third line after targeted therapy, but is becoming more of a frontline therapy treatment for kidney cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains why chemotherapy has no role for patients with kidney cancer. She argues that targeted therapy and immunotherapy are now mostly used for kidney cancer treatment. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses the research that she thought was most intriguing at Annual Meeting GU. She states that immunotherapy has been the most exciting topic presented. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

At Patient Power’s 2016 town meeting at Levine Cancer Institute in Charlotte, Dr. Srdan Verstovsek explains why MPNs cause night sweats. Dr. Verstovsek discusses the reason symptoms are associated with this systemic disease and how doctors try to counteract those symptoms, including targeting inflammation and cell growth. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how emerging data on resistance has changed treatment for advanced prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how CHAARTED and STAMPEDE impacted his treatment for patients with metastatic hormone sensitive prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.